| Literature DB >> 32867051 |
Mingshu Cui1, Wei Zhang1, Luyao Xie1, Lu Chen1, Lu Xu1.
Abstract
Because of its tunable textural properties and chirality feature, chiral mesoporous silica (CMS) gained significant consideration in many fields and has been developed rapidly in recent years. In this review, we provide an overview of synthesis strategies for fabricating CMS together with its main applications. The properties of CMS, including morphology and mesostructures and enantiomer excess (ee), can be altered according to the synthetic conditions during the synthesis process. Despite its primary stage, CMS has attracted extensive attention in many fields. In particular, CMS nanoparticles are widely used for enantioselective resolution and adsorption of chiral compounds with desirable separation capability. Also, CMS acts as a promising candidate for the effective delivery of chiral or achiral drugs to produce a chiral-responsive manner. Moreover, CMS also plays an important role in chromatographic separations and asymmetric catalysis. There has been an in-depth review of the synthetic methods and mechanisms of CMS. And this review aims to give a deep insight into the synthesis and application of CMS, especially in recent years, and highlights the significance that it may have in the future.Entities:
Keywords: application; chirality; mesoporous silica; synthesis
Mesh:
Substances:
Year: 2020 PMID: 32867051 PMCID: PMC7504517 DOI: 10.3390/molecules25173899
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The synthesis method, morphology, and textural properties of chiral mesoporous silica.
| Synthesis Method | Morphology | Textural Properties | References | ||
|---|---|---|---|---|---|
| Specific Surface Area | Pore Diameter | Pore Volume | |||
| Chiral anionic surfactant C14- | Twisted hexagonal rod-like | 600 | 2.20 | 0.37 | [ |
| Chiral anionic amphiphilic molecules ( | Twisted hexagonal rod-like | 577–974 | 2.40–2.96 | 0.43–0.90 | [ |
| Chiral anionic surfactant C14- | Twisted-ribbon-like and various twisted-rod-like | 400 | 3.60 | 0.50 | [ |
| Achiral CTAB as template and a chiral metal complex Λ-[Co(+)(chxn)3]I3 as contemplate. | Twisted hexagonal rod-like | 1047 | 2.60 | 1.90 | [ |
| Chiral anionic surfactants C14- | Twisted hexagonal rod-like | 603; 735 | 2.20 | N/A | [ |
| Chiral anionic surfactant, C14- | Twisted hexagonal rod-like | 853 | 2.10 | 0.66 | [ |
| Chiral anionic surfactant C16- | Twisted hexagonal rod-like | N/A | N/A | N/A | [ |
| Chiral anionic surfactant | Twisted hexagonal rod-like | 496–884 | 2.10–3.20 | 0.23–0.99 | [ |
| Chiral cationic surfactant | Helical | 730 | 3.80 | 1.56 | [ |
| Chiral cationic gelators | Helical, balls | 354; 628 | 5.20; 5.00 | N/A | [ |
| Room-temperature ionic liquids 1-octadecyl-3-methylimidazolium bromide as template | Helical | 893 | 3.270 | 0.99 | [ |
| Achiral cationic surfactant CTAB as template. | Helical | 998 | 2.80 | N/A | [ |
| Achiral cationic surfactant CTAB and perfluorooctanoic acid as co-templates. | Helical rod-like | 462–635 | 2.60 | 0.59–0.73 | [ |
| Achiral cationic surfactant CTAB as template and achiral alcohols as CSDA. | Helical | 459–842 | 2.00–4.20 | N/A | [ |
| CTAB as a template and either | Twisted hexagonal rod-like | 930; 1329 | 6.83; 6.97 | 1.40; 2.30 | [ |
| Achiral cationic surfactant CTAB as template. | Helical rod-like | 1027 | 3.40 | 1.02 | [ |
| Achiral cationic surfactant C18-TMS as a template in the presence of arginine, histidine, isoleucine, and proline in basic media. | Pores with an “eight-like” morphology | 840–1130 | 2.80–3.30 | 0.80–1.13 | [ |
| Tetraethyl orthosilicate and quaternized aminosilane as silica sources together with | Irregular | 730 | 2.30–2.50 | 0.47 | [ |
| Achiral cationic surfactant CTAB as template together with APTTES- | Spherical | 565; 387 | 3.30; 3.20 | 0.40; 0.30 | [ |
| Achiral cationic surfactant CTAB as template together with APTTES- | Spherical | 578; 441 | 3.47; 2.98 | 0.50; 0.33 | [ |
| Achiral cationic surfactant STAB as template together with APTTES- | Spherical | 571; 585 | 2.71; 2.74 | 0.69; 0.75 | [ |
| Achiral cationic surfactant STAB as template together with APTTES- | Spherical | 441; 474 | 2.20; 4.30 | 0.36; 1.10 | [ |
N-myristoyl-l-alanine sodium salt (C14-l-AlaS), N-trimethoxysilylpropyl-N,N,N-trimethylammonium chloride (TMAPS), 3-aminopropyltrimethoxysilane (APS), co-structure-directing agent (CSDA), 3-aminopropyltriethoxysilane (APTES), N-myristoyl-l/d-alanine (C14-l/d-AlaA), N-Palmitoyl-l-Ala (C16-l-Ala), N-palmitoyl-l-Val (C16-l-Val), N-palmitoyl-l-Ile (C16-l-Ile), and N-palmitoyl-l-Phe (C16-l-Phe), cetyltrimethylammonium bromide (CTAB), N-3 [3-(trimethoxysilyl)propyl]-N-octadecyl-N,N-dimethylammonium chloride (C18-TMS), Stearyltrimethylammonium Bromide (STAB).
Figure 1(A) Schematic diagram of CMS synthesis by surfactants; (B) Factors contributing to the synthetic control of CMS. Credit: original figure.
Figure 2Molecular origin of the left-handed (left) and right-handed (right) helical structure of the CMS derived from the helical propellerlike packing of the chiral amphiphilic molecules. Credit: reprinted with permission from Reference [37]. Copyright 2008 American Chemical Society.
Figure 3(a) TEM image of calcined mesoporous silica nanofibers (preparation condition: (10 mg l-4PyCl: 0.9 mL 1.0 wt% NH3 aq.: 0.1 mL ethanol: 20 mg TEOS)); (b) SEM and (c) TEM images of calcined mesoporous silica nanofibers (Preparation condition: (10 mg l-4PyCl: 0.6 mL 1.0 wt% NH3 aq.: 0.4 mL ethanol: 20 mg TEOS)); (d,f) SEM and (e,g) TEM images of calcined mesoporous silica nanofibers (preparation condition: (10 mg l-4PyCl: 0.7 mL 11.3 wt%NH3 aq.: 0.3 mL ethanol: 20 mg TEOS)). (h) SEM image of calcined mesoporous silica nanofibers (Preparation condition: (10 mg l-4PyCl: 0.5 mL 1.0 wt% NH3 aq.: 0.5 mL ethanol: 20 mg TEOS)). Credit: republished with permission of Royal Society of Chemistry, from [38], Copyright (2005); permission conveyed through Copyright Clearance Center, Inc.
Figure 4(A) SEM images (left), high-magnification SEM images (inset), and TEM images (right) for (a) CMS-20, (b) CMS-15, (c) CMS-10, and (d) CMS-5; (B): (a,c) SEM and (b,d) TEM images of mesoporous silica synthesized with C14TMAB in (a,b) 25 wt% and (c,d) 20 wt% ammonia solution. Credit: republished with permission of John Wiley and Sons, from [43], Copyright (2007), permission conveyed through Copyright Clearance Center, Inc.
Figure 5Schematic drawing illustrating the formation of helical mesostructured rods from hexagonally arrayed straight rod-like micelles with equal length (A) to a helical rod with two rounded ends viewed perpendicular to the length direction (B) and the hexagonal cross-section viewed parallel to the length direction (C). Credit: reprinted with permission from [44]. Copyright 2006 American Chemical Society.
Figure 6(A) TEM micrograph of the calcined material showing the different orientation of the mesopores, which may induce the chirality. The “eight-like” domain is marked by the dashed square, while the inset corresponds to a different particle. (B) The sector of the suggested micelle constituted by alternating C18-TMS dimers and amino acid (proline) molecules or negatively charged silica species. The organization of the aminosilane dimers into micelles serves as a template for the formation of the ordered mesoporous silica, while the amino acid transfers its chirality to the micelle and from there to the silica. Credit: reprinted with permission from [48]. Copyright 2011 American Chemical Society.
Figure 7Various applications of CMS. Credit: original figure.
Applications of CMS in various fields.
| Applications | Compound or Drug | Key Points | Reference |
|---|---|---|---|
| Enantioselective adsorption | With a chiral selectivity factor of 3.15 | [ | |
| Enantioselective adsorption | [ | ||
| Enantioselective adsorption | Racemic valine | With a chiral selectivity factor of 5.22 | [ |
| Enantioselective resolution | Racemic valine and alanine | With a chiral selectivity factor of 7.52 for alanine and high enantiomeric excess of ca. 45% for valine | [ |
| Enantioselective resolution | Racemic proline, isoleucine, trans-4-hydroxyproline, pipecolic acid, valine, leucine, and phenylglycine | The CMS prepared via chiral imprinting still exhibits enantioselectivity for racemic mixtures after calcination. | [ |
| Stereoselective adsorption | [ | ||
| Enantiomeric adsorption | Supramolecular templated materials prepared with guanosine monophosphate (NGM-1) and folic acid have opposite enantiomeric selectivity for enantiomeric pairs | [ | |
| Chromatographic separations | Isomers, PAHs, linear alkanes, long-chain alkanes, Grob’stest mixture, aromatic hydrocarbons, and chiral compounds | As stationary phase for high-resolution gas chromatography separations | [ |
| Chromatographic separations | Phenylalanine, tryptophan, glutamic, alanine, serine, aspartic acid, cysteine, methionine, tyrosine, and histidine | As chiral stationary phase, with hydroxypropyl-β-cyclodextrin (HP-β-CD) as the chiral selector for enantioseparation using MCE | [ |
| Chiral drug delivery | Levofloxacin | In vitro sustained drug release and antibacterial activity of levofloxacin | [ |
| Chiral drug delivery | Metoprolol | In vitro enantioselective controlled release | [ |
| Chiral drug delivery | Ibuprofen | Release differentiation, controlled release in vitro, favorable oral bioavailability, elimination half-life, and anti-inflammatory effect in vivo. | [ |
| Achiral drug delivery | Aspirin | In vitro controlled release | [ |
| Achiral drug delivery | Indomethacin | Improved in vitro dissolution of poorly water-soluble drug | [ |
| Achiral drug delivery | Curcumin | Improved in vitro dissolution of poorly water-soluble drug | [ |
| Achiral drug delivery | Nimodipine | Improved in vitro dissolution; enhanced bioavailability, therapeutic effect, and brain distribution in vivo | [ |
| Achiral drug delivery | Indometacin | Improved in vitro dissolution; enhanced in vivo oral bioavailability and anti-inflammatory effect | [ |
| Achiral drug delivery | Indometacin | Different chiral recognition functions in the in-vitro chiral dissolution medium | [ |
| Achiral drug delivery | Nimesulide | Different chiral recognition functions in the in-vitro chiral dissolution medium; enhanced in vivo oral bioavailability and anti-inflammatory effect | [ |
| Achiral drug delivery | Nimesulide | Improved in vitro dissolution; enhanced bioavailability and anti-inflammatory effect in vivo | [ |
| Asymmetric catalysis | Diisopropylzinc, pyrimidine-5-carbaldehyde 1 | A chiral inorganic trigger of asymmetric autocatalysis | [ |
Figure 8In vitro release profiles of (A): (a) IBU, (b) IBU loaded l-CMS, (c) IBU loaded d-CMS in simulated intestinal fluid (SIF) (the inset figure is the enlargement of the rectangle area labeled in Figure (A); (B): (a) IBU, (b) IBU loaded l-CMS, (c) IBU loaded d-CMS in simulated gastric fluid (SGF). Credit: republished with permission of Elsevier, from Reference [104], Copyright (2019), permission conveyed through Copyright Clearance Center, Inc.
Figure 9Molecular Simulation results of (A), IMC loaded N-MSN; (B), IMC loaded Cb-d-MSN; (C), IMC loaded Cb-l-MSN. Credit: republished with permission of Elsevier, from Reference [50], Copyright (2018), with permission conveyed through Copyright Clearance Center, Inc.
Figure 10(A) In vitro release profiles of NMS, NMS loaded FL-MSNs, and NMS loaded FD-MSNs in pH 6.8 PBS. (B) In vitro release profiles of NMS, NMS loaded FL-MSNs, and NMS loaded FD-MSNs in l-Ala-PBS or d-Ala-PBS. Credit: republished with permission of Elsevier, from Reference [52], Copyright (2020), permission conveyed through Copyright Clearance Center, Inc.